Organogenesis Holdings Inc. (FRA:2PQ)

Germany flag Germany · Delayed Price · Currency is EUR
3.920
-0.440 (-10.09%)
At close: Jan 2, 2026
30.67%
Market Cap459.34M
Revenue (ttm)396.51M
Net Income (ttm)-7.86M
Shares Outn/a
EPS (ttm)-0.07
PE Ration/a
Forward PE16.91
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume82
Open4.360
Previous Close4.360
Day's Range3.920 - 4.360
52-Week Range2.300 - 6.000
Betan/a
RSI32.97
Earnings DateFeb 27, 2026

About Organogenesis Holdings

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company’s advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic fo... [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Gary Gillheeney
Employees 869
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 2PQ
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

Organogenesis Initiates BLA Submission For ReNu In Knee Arthritis

(RTTNews) - Organogenesis Holdings Inc. (ORGO) ,a regenerative medicine company announced that it has initiated the submission of a Biologics License Application or BLA to the US Food and Drug Adminis...

18 days ago - Nasdaq

Organogenesis (ORGO) Advances ReNu BLA Submission for Knee Arthritis

Organogenesis (ORGO) Advances ReNu BLA Submission for Knee Arthritis

18 days ago - GuruFocus

Organogenesis (ORGO) Begins Rolling Submission for FDA Approval of ReNu

Organogenesis (ORGO) Begins Rolling Submission for FDA Approval of ReNu

19 days ago - GuruFocus

Organogenesis Announces Initiation of Biologics License Application for ReNu

Initial modules submitted to FDA under rolling review; final modules expected in the first half of 2026 CANTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a l...

19 days ago - Wallstreet:Online

Organogenesis Announces Initiation of Biologics License Application for ReNu®

Initial modules submitted to FDA under rolling review; final modules expected in the first half of 2026 Initial modules submitted to FDA under rolling review; final modules expected in the first half ...

19 days ago - GlobeNewsWire

Organogenesis To File Rolling BLA For ReNu Following FDA Meeting

(RTTNews) - Organogenesis Holdings Inc. (ORGO) announced the successful completion of a planned Type-B meeting with the U.S. FDA, confirming that the company may initiate a rolling Biologics License A...

26 days ago - Nasdaq

Organogenesis (ORGO) Advances ReNu Program With FDA Filing

Organogenesis (ORGO) Advances ReNu Program With FDA Filing

27 days ago - GuruFocus

Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu for Knee Osteoarthritis Pain

Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025 CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading r...

27 days ago - Wallstreet:Online

Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain

Clinical Development Program Appropriate for Rolling BLA  Submission Expected by the End of 2025 CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading ...

27 days ago - GlobeNewsWire

Organogenesis (ORGO) Q3 Earnings Exceed Expectations with Strong Product Sales

Organogenesis (ORGO) Q3 Earnings Exceed Expectations with Strong Product Sales

2 months ago - GuruFocus

Organogenesis Stock Surges 54% After Q3 Revenue Beat And Guidance Raise

(RTTNews) - Organogenesis Holdings Inc. (ORGO) jumped 53.72% to $5.98, up $2.09, after reporting strong third-quarter 2025 results and revising its full-year outlook.

2 months ago - Nasdaq

Organogenesis Holdings Inc (ORGO) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ...

Organogenesis Holdings Inc (ORGO) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Positioning Amid Challenges

2 months ago - GuruFocus

Q3 2025 Organogenesis Holdings Inc Earnings Call Transcript

Q3 2025 Organogenesis Holdings Inc Earnings Call Transcript

2 months ago - GuruFocus

Organogenesis Holdings Inc (ORGO) Q3 2025 Earnings: EPS of $0. ...

Organogenesis Holdings Inc (ORGO) Q3 2025 Earnings: EPS of $0.11 Beats Estimate, Revenue Surges to $150.5 Million

2 months ago - GuruFocus

Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance

CANTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p...

2 months ago - GlobeNewsWire

Organogenesis Applauds CMS's Significant Step In Payment Reform

With evidence-based portfolio including technologies in each FDA category, we believe we are best positioned in the skin substitutes market for 2026 and beyond With evidence-based portfolio including ...

2 months ago - GlobeNewsWire

Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CANTON, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (the “Company”) (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commer...

2 months ago - GlobeNewsWire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO

NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. ("Organogenesis" or the "Company") (NASDAQ: ORGO). Such investors a...

2 months ago - PRNewsWire

Organogenesis Holdings Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ORGO

LOS ANGELES--(BUSINESS WIRE)--Organogenesis Holdings Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ORGO.

3 months ago - Business Wire